| Dr Robert Edward Tarpy, MD | |
|
1153 Centre St, Suite 4990, Boston, MA 02130-3446 | |
| (617) 983-7000 | |
| (617) 522-4156 |
| Full Name | Dr Robert Edward Tarpy |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 36 Years |
| Location | 1153 Centre St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770640781 | NPI | - | NPPES |
| 3137333 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 72824 (Massachusetts) | Primary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | 72824 (Massachusetts) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Faulkner Hospital-brigham And Women's | Boston, MA | Hospital |
| Brigham And Women's Hospital | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brigham And Women's Physicians Organization Inc | 3870405988 | 2510 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase, being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia, ineligible for intensive remission induction therapy.
Olympic swimmer and television personality Sharron Davies MBE was in Nottingham this week to open a new clinical trials unit that will take treatments for respiratory illnesses such as asthma from laboratory bench to bedside.
OncoMed Pharmaceuticals, Inc. and Fluidigm Corporation today announced a new initiative to apply Fluidigm's unique microfluidic tools to the analysis of tumor cell heterogeneity, including cancer stem cells.
Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson's disease.
› Verified 5 days ago
| Entity Name | Brigham And Women's Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033535497 PECOS PAC ID: 3870405988 Enrollment ID: O20150107001260 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase, being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia, ineligible for intensive remission induction therapy.
Olympic swimmer and television personality Sharron Davies MBE was in Nottingham this week to open a new clinical trials unit that will take treatments for respiratory illnesses such as asthma from laboratory bench to bedside.
OncoMed Pharmaceuticals, Inc. and Fluidigm Corporation today announced a new initiative to apply Fluidigm's unique microfluidic tools to the analysis of tumor cell heterogeneity, including cancer stem cells.
Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson's disease.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robert Edward Tarpy, MD 1153 Centre St, Suite 4990, Boston, MA 02130-3446 Ph: (617) 983-7000 | Dr Robert Edward Tarpy, MD 1153 Centre St, Suite 4990, Boston, MA 02130-3446 Ph: (617) 983-7000 |
News Archive
Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase, being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia, ineligible for intensive remission induction therapy.
Olympic swimmer and television personality Sharron Davies MBE was in Nottingham this week to open a new clinical trials unit that will take treatments for respiratory illnesses such as asthma from laboratory bench to bedside.
OncoMed Pharmaceuticals, Inc. and Fluidigm Corporation today announced a new initiative to apply Fluidigm's unique microfluidic tools to the analysis of tumor cell heterogeneity, including cancer stem cells.
Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson's disease.
› Verified 5 days ago
Kaitlyn My-tu Lam, MBBS Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |